IL-33, an Important Biomarker in Non-small-cell Lung Cancer?

  • Published : 2013.12.31




  1. Bergis D, Kassis V, Ranglack A, et al (2013). High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol, 6, 311-8.
  2. Farjadfar A, Mojtahedi Z, Ghayumi MA, et al (2009). Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol, 48, 971-6.
  3. Gao K, Li X, Zhang L, et al (2013). Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett, 335, 463-71.
  4. Hu LA, Fu Y, Zhang DN, Zhang J (2013). Serum IL-33 as a Diagnostic and Prognostic Marker in Non- small Cell Lung Cancer. Asian Pac J Cancer Prev, 14, 2563-6.
  5. Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2013). Angiogenic axis angiopoietin-1 and angiopoietin-2/tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol, 788, 341-8.
  6. Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2012). Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer? Exp Oncol, 34, 348-53.
  7. Rovina N, Hillas G, Dima E, et al. (2011) VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine, 54, 277-81.
  8. Sun P, Ben Q, Tu S, et al. (2011) Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci, 56, 3596-601.

Cited by

  1. IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2–ERK1/2 Pathway vol.60, pp.5, 2015,
  2. IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer vol.314, pp.3, 2018,